Black Rock Inc. Verona Pharma PLC Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Verona Pharma PLC stock. As of the latest transaction made, Black Rock Inc. holds 430,429 shares of VRNA stock, worth $19.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

430,429

Previous 381,717 12.76%

Holding current value

$19.4 Million

Previous $6.14 Million 1.35%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$11.48 - $17.02 $559,213 - $829,078	48,712 Added 12.76%	430,429 $6.22 Million
Q1 2024 May 10, 2024	BUY	$15.3 - $20.24 $261,691 - $346,184	17,104 Added 4.69%	381,717 $6.14 Million
Q4 2023 Feb 13, 2024	BUY	$11.94 - $20.47 $343,991 - $589,740	28,810 Added 8.58%	364,613 $7.25 Million
Q3 2023 Nov 13, 2023	SELL	$16.3 - $22.09 $533,939 - $723,602	-32,757 Reduced 8.89%	335,803 $5.47 Million
Q2 2023 Aug 11, 2023	BUY	$19.41 - $23.43 $414,092 - $499,855	21,334 Added 6.14%	368,560 $7.79 Million
Q1 2023 May 12, 2023	BUY	$18.06 - $25.27 $34,332 - $48,038	1,901 Added 0.55%	347,226 $6.97 Million
Q4 2022 Feb 13, 2023	BUY	$9.84 - $26.13 $3.4 Million - $9.02 Million	345,312 Added 2656246.25%	345,325 $9.02 Million
Q2 2022 Aug 12, 2022	BUY	$3.55 - $5.06 $46 - $65	13 New	13 $0
Q4 2021 Feb 10, 2022	SELL	$3.91 - $7.08 $960,272 - $1.74 Million	-245,594 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$5.29 - $6.35 $22,995 - $27,603	-4,347 Reduced 1.74%	245,594 $1.35 Million
Q2 2021 Aug 11, 2021	BUY	$5.72 - $9.09 $1.43 Million - $2.27 Million	249,941 New	249,941 $1.64 Million

Others Institutions Holding VRNA

# of Institutions

167

Shares Held

68.7M

Call Options Held

704K

Put Options Held

685K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account